YEARS

1990-1995

AUTHORS

Jonathan A Fletcher

TITLE

MOLECULAR CYTOGENETICS OF SOLID TUMORS

ABSTRACT

This physician-Scientist Award will enable Dr. Fletcher to acquire a broad and thorough training in the fields of experimental cytogenetics and molecular biology. In each phase of the award, these skills will be applied to specific research questions in the field of oncology. Phase I will be conducted under the co-sponsorship of Drs. Cynthia C. Morton and Philip Leder, in the Department of Pathology and Genetics, respectively, at Harvard Medial School. A primary focus of this phase will be to localize the causative gene for nevoid basal cell carcinoma syndrome. During Phase I, Dr. Fletcher will also participate in seminars and courses at Harvard Medical School and at the Jackson Laboratory, and will continue extensive work-in-progress on solid tumor cytogenetics. The solid tumor cytogenetics projects will include: 1) identification of characteristic chromosome rearrangements in specific malignancies; 2) investigation of the diagnostic significance of specific cytogenetic patterns in mesenchymal tumors; and 3) determination of the extent and role of genetic instability in adult malignancies. Dr. Samuel E. Lux, Chief of the Hematology-Oncology Division at The Children's Hospital, Boston, and Dr. STeven J. Burakoff, Chief, Division of Pediatric Oncology, Dana-Fraber Cancer Institute, will co-sponsor Phase II of this award. During Phase II, Dr. Fletcher will establish a laboratory devoted to the cytogenetic and molecular characterization of solid tumors at the Dana-Farber Cancer Institute. This laboratory will utilize cytogenetic findings as a basis for subsequent molecular investigations into the etiologies of solid tumors.

FUNDED PUBLICATIONS

  • Identification of genetically aberrant cell lineages in Wilms' tumors.
  • Chromosome aberrations in desmoid tumors. Trisomy 8 may be a predictor of recurrence.
  • Clonal 6p21 rearrangement is restricted to the mesenchymal component of an endometrial polyp.
  • Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains.
  • Extremely poor prognosis of pediatric acute lymphoblastic leukemia with translocation (9;22): updated experience.
  • Trisomy 5 and trisomy 7 are nonrandom aberrations in pigmented villonodular synovitis: confirmation of trisomy 7 in uncultured cells.
  • Cytogenetic evidence for a chromosome 22 tumor suppressor gene in ependymoma.
  • Fluorescent in situ hybridization assessment of chromosome 7 copy number in uncultured lung and kidney cells.
  • Molecular characterization of a 17q11.2 translocation in a malignant schwannoma cell line.
  • Fibrosarcoma in infants and children. Application of new techniques.
  • Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: infrequent detection of the t(2;5) in extranodal lymphomas.
  • Cytogenetic and histologic findings in 17 pulmonary chondroid hamartomas: evidence for a pathogenetic relationship with lipomas and leiomyomas.
  • Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors.
  • Isolation and characterization of a mammalian homolog of the Drosophila white gene.
  • Cytogenetic findings in pediatric adipose tumors: consistent rearrangement of chromosome 8 in lipoblastoma.
  • How to use: Click on a object to move its position. Double click to open its homepage. Right click to preview its contents.

    Download the RDF metadata as:   json-ld nt turtle xml License info


    30 TRIPLES      15 PREDICATES      31 URIs      7 LITERALS

    Subject Predicate Object
    1 grants:56c9353bd61880b2604a072f6283ac70 sg:abstract This physician-Scientist Award will enable Dr. Fletcher to acquire a broad and thorough training in the fields of experimental cytogenetics and molecular biology. In each phase of the award, these skills will be applied to specific research questions in the field of oncology. Phase I will be conducted under the co-sponsorship of Drs. Cynthia C. Morton and Philip Leder, in the Department of Pathology and Genetics, respectively, at Harvard Medial School. A primary focus of this phase will be to localize the causative gene for nevoid basal cell carcinoma syndrome. During Phase I, Dr. Fletcher will also participate in seminars and courses at Harvard Medical School and at the Jackson Laboratory, and will continue extensive work-in-progress on solid tumor cytogenetics. The solid tumor cytogenetics projects will include: 1) identification of characteristic chromosome rearrangements in specific malignancies; 2) investigation of the diagnostic significance of specific cytogenetic patterns in mesenchymal tumors; and 3) determination of the extent and role of genetic instability in adult malignancies. Dr. Samuel E. Lux, Chief of the Hematology-Oncology Division at The Children's Hospital, Boston, and Dr. STeven J. Burakoff, Chief, Division of Pediatric Oncology, Dana-Fraber Cancer Institute, will co-sponsor Phase II of this award. During Phase II, Dr. Fletcher will establish a laboratory devoted to the cytogenetic and molecular characterization of solid tumors at the Dana-Farber Cancer Institute. This laboratory will utilize cytogenetic findings as a basis for subsequent molecular investigations into the etiologies of solid tumors.
    2 sg:endYear 1995
    3 sg:hasContribution contributions:75a47be728888bf28106c41ea4628a30
    4 sg:hasFieldOfResearchCode anzsrc-for:11
    5 anzsrc-for:1112
    6 sg:hasFundedPublication articles:25eed1064e2e1c5d396122421bb0fca1
    7 articles:2d41afd392d8534086f35db4e441f602
    8 articles:3617cb1c1e876b366cb8b35cf4c5687c
    9 articles:4d77c64b7c7be7db60b49a6591f57c44
    10 articles:6adfb670dc3cddfe7eebeb64deaf1b22
    11 articles:6bad730c1f8ca2bc653faee4824c9b04
    12 articles:705544c49f80fc8700e3d6376b6f7029
    13 articles:79be441604614bb4933b3a2840aa79e8
    14 articles:7b45fae65058eb96f7a67f4e25824a37
    15 articles:7b687e3f5dbcacc7921dac06ed1d5ae5
    16 articles:86308426fa3b3a7a0f9537ae533578e9
    17 articles:8cb4df473c9389c86ee4d262a1273463
    18 articles:c77ebe1ee8ad38855a4fdbdbfd791148
    19 articles:db10c9f163ffe95b6f79434929dcb9e4
    20 articles:f9e984bc22cab4f7276f78de88208a7d
    21 sg:hasFundingOrganization grid-institutes:grid.48336.3a
    22 sg:hasRecipientOrganization grid-institutes:grid.62560.37
    23 sg:language English
    24 sg:license http://scigraph.springernature.com/explorer/license/
    25 sg:scigraphId 56c9353bd61880b2604a072f6283ac70
    26 sg:startYear 1990
    27 sg:title MOLECULAR CYTOGENETICS OF SOLID TUMORS
    28 sg:webpage http://projectreporter.nih.gov/project_info_description.cfm?aid=2084049
    29 rdf:type sg:Grant
    30 rdfs:label Grant: MOLECULAR CYTOGENETICS OF SOLID TUMORS
    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular JSON format for linked data.

    curl -H 'Accept: application/ld+json' 'http://scigraph.springernature.com/things/grants/56c9353bd61880b2604a072f6283ac70'

    N-Triples is a line-based linked data format ideal for batch operations .

    curl -H 'Accept: application/n-triples' 'http://scigraph.springernature.com/things/grants/56c9353bd61880b2604a072f6283ac70'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'http://scigraph.springernature.com/things/grants/56c9353bd61880b2604a072f6283ac70'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'http://scigraph.springernature.com/things/grants/56c9353bd61880b2604a072f6283ac70'






    Preview window. Press ESC to close (or click here)


    ...